Thomas Leblanc, MD, MA, MHS, FAAHPM, and Daniel George, MD, have been named Fellows of the American Society of Clinical Oncology (FASCO), ASCO announced last week in a press release introducing the 2021 FASCO class and presenting other special awards.
The FASCO distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO.
Dr. LeBlanc’s clinical practice focuses on the care of patients with myeloid malignancies and acute leukemias, including AML, ALL, MDS, CML, and related diseases. His research uses both quantitative and qualitative methods to better understand the patient experience of living with (and being treated for) blood cancer, which informs interventions such as integrated palliative care to improve those experiences.
LeBlanc is an associate professor of medicine (Hematologic Malignancies and Cellular Therapy) and an associate professor in the Department of Population Health Sciences. He first joined the Department of Medicine faculty as a medical instructor in 2010 and in 2013 became an assistant professor in the Department. He’s been a member of Duke Cancer Institute since 2013.
Dr. George, who co-leads the DCI Center for Prostate and Urologic Cancers and the Patierno/George/Freedman Lab for Cancer Research, is an internationally recognized clinical oncologist, researcher and thought leader in genitourinary malignancies — specializing in kidney cancer and prostate cancer. His areas of research include improved treatment modalities, the development of new drugs, and the identification of biomarkers in GU cancers with an emphasis on the biological drivers of cancer disparities. He’s the author of more than 200 peer-reviewed publications, including several reviews and position papers on GU cancer disparities.
George is a tenured professor of medicine (Medical Oncology), with a secondary appointment in the Department of Surgery, Division of Urology. He received both his BS (1988) and his MD (1992) at Duke and did his residency and fellowship at Johns Hopkins Hospital. George joined the DCI faculty in 2003 from Harvard University Medical School's Dana-Farber Cancer Institute, where he was an assistant professor of medicine.
George has been a member of ASCO since 2003. His roles with ASCO have included serving on the Scientific Committee for the Genitourinary Cancer Symposium for three years; serving twice on the ASCO Scientific Program Committee (two three-year terms); serving one three-year term as leader of the Scientific Program Committee GU (Non-prostate) Cancer Track; and serving two three-year terms on the Conquer Cancer Foundation grants review committee, including one as chair. He has also, as a volunteer, led GU fellows on poster walks and has volunteered at mentorship luncheons.
Most recently (since 2019), George has been serving as a member of the ASCO Research Priorities Decision Group.